Reaction: Daunorubicin to 1 product

Reaction
Reaction type
reduction
Direction
Major circulating metabolite?
Yes
Spontaneous?
No
Activity
active
References
  1. Takanashi S, Bachur NR: Daunorubicin metabolites in human urine. J Pharmacol Exp Ther. 1975 Oct;195(1):41-9. [Article]
  2. Loveless H, Arena E, Felsted RL, Bachur NR: Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res. 1978 Mar;38(3):593-8. [Article]
  3. Piska K, Koczurkiewicz P, Bucki A, Wojcik-Pszczola K, Kolaczkowski M, Pekala E: Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents. Invest New Drugs. 2017 Jun;35(3):375-385. doi: 10.1007/s10637-017-0443-2. Epub 2017 Mar 10. [Article]
  4. FDA Approved Drug Products: VYXEOS (daunorubicin and cytarabine) liposome for injection, for intravenous use [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Aldo-keto reductase familyNot AvailableNot Availableconfirmed
Carbonyl reductase [NADPH] 1Not AvailableNot Availableconfirmed
Carbonyl reductase [NADPH] 3Not AvailableNot Availableconfirmed